How Quickly Does Kesimpta Deplete B Cells?
Kesimpta (ofatumumab), a CD20 monoclonal antibody, depletes CD20-positive B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis. In clinical studies, significant B cell depletion occurs rapidly after the first subcutaneous dose.
- Median time to first confirmed CD19+ B cell count below 20/μL (a marker for depletion) is 1 week.[1][2]
- By week 2, over 90% of patients achieve near-complete depletion (<5 CD19+ B cells/μL).[1]
- Full depletion typically stabilizes by 4-6 weeks, with counts remaining low throughout treatment (monthly dosing after initial doses).[2][3]
This fast onset supports its use in relapsing multiple sclerosis, unlike slower oral therapies.
What Influences Depletion Speed?
Individual factors like baseline B cell count, body weight, and anti-drug antibodies can cause minor variations, but population-level data shows consistency across trials.[1]
Higher doses (e.g., 20 mg starting) deplete faster than lower ones in dose-ranging studies.[3]
How Long Until B Cells Recover After Stopping?
B cell repopulation begins 4-6 months post-discontinuation, reaching 50% of baseline by 6-9 months and full recovery by 12-18 months in most patients.[1][2]
Monitoring via flow cytometry is recommended if infection risk persists.
Does This Differ from Other Anti-CD20 Therapies?
| Therapy | Time to >95% Depletion | Dosing |
|---------|-------------------------|--------|
| Kesimpta | 1-2 weeks | SC monthly |
| Ocrevus (ocrelizumab) | 2-4 weeks | IV every 6 months |
| Rituxan (rituximab) | 2-4 weeks | IV variable |
Kesimpta's subcutaneous route and humanized antibody enable quicker, deeper depletion with less infusion time.[3][4]
Patient Concerns: Monitoring and Risks
Depletion increases infection risk (e.g., upper respiratory), peaking early and resolving with repopulation. Guidelines recommend annual flu shots pre-treatment and HBV screening.[2]
No routine B cell monitoring is required during steady-state therapy.[1]
[1]: Kesimpta Prescribing Information (Novartis)
[2]: ASCLEPIOS I/II Trials (NEJM, 2020)
[3]: MIRROR Study (Lancet Neurol, 2018)
[4]: DrugPatentWatch.com - Ofatumumab Patents